- Featured Product
- KD/KO Validated
FABP4 Polyclonal antibody, PBS Only
FABP4 Polyclonal Antibody for WB, IHC, Indirect ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human, mouse, rat
Applications
WB, IHC, Indirect ELISA
Conjugate
Unconjugated
Cat no : 12802-1-PBS
Synonyms
Validation Data Gallery
Tested Applications
Recommended dilution
Application | Dilution |
---|---|
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. |
Product Information
12802-1-PBS targets FABP4 in WB, IHC, Indirect ELISA applications and shows reactivity with human, mouse, rat samples.
Tested Reactivity | human, mouse, rat |
Host / Isotype | Rabbit / IgG |
Class | Polyclonal |
Type | Antibody |
Immunogen | FABP4 fusion protein Ag3912 相同性解析による交差性が予測される生物種 |
Full Name | fatty acid binding protein 4, adipocyte |
Calculated molecular weight | 132 aa, 15 kDa |
Observed molecular weight | 15 kDa |
GenBank accession number | BC003672 |
Gene symbol | FABP4 |
Gene ID (NCBI) | 2167 |
RRID | AB_2102442 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Antigen affinity purification |
Storage Buffer | PBS Only |
Storage Conditions | Store at -80°C. |
Background Information
Fatty acid binding protein (FABP) 4 is a member of the FABP family which abundantly expressed, fatty acid carrier proteins. FABPs are capable of binding a variety of hydrophobic molecules such as long-chain fatty acids and are important for their uptake and intracellular trafficking. It was first identified as an adipocyte-specific protein, important for the maintenance of lipid and glucose metabolism. It is also detected in macrophages, where it participates in regulating inflammation and cholesterol trafficking via NFκB and PPAR. In more recent studies, FABP4 has been found in a variety of endothelial cells, where it has been identified as a target of VEGF and a regulator of cell proliferation and possibly angiogenesis. Pathologically, FABP4 has been associated with the development of metabolic syndrome, diabetes and cancer and vulnerability of atherosclerotic plaques. FABP4 has been identified as a novel prognostic factor for both adverse cardiovascular events and breast cancer.